Study Testing the Efficacy, Safety, and Tolerability of EDI048 in Cryptosporidium Infection Model in Healthy Adults

NCT07249463 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

96

Enrollment

INDUSTRY

Sponsor class

Conditions

Cryptosporidiosis

Interventions

BIOLOGICAL: Cryptosporidium parvum oocysts (ABO809)
DRUG: EDI048
OTHER: Placebo

Sponsor

Novartis Pharmaceuticals